蛋白质分解向基因组的CD36介导的内细胞分裂
Zhengyu Wang1, Bo-Syong Pan2, Rajesh Kumar Manne2
1Department of Pharmacology, The Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA; Department of Pharmaceutical Science, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
研究人员发现CD36蛋白质有助于吸收大型药物,如向蛋白质分解的仿真体 (PROTACs). 修改PROTACs以结合CD36通过改善细胞透性和溶解性来增强它们的抗瘤功效.
科学领域:
- 药物输送和药物化学
- 分子和细胞生物学
- 生物化学
背景情况:
- 被动扩散限制了大型和极性分子的细胞膜透,包括向蛋白解的仿真体 (PROTACs).
- 了解细胞吸收这种疗法的机制对于提高疗效至关重要.
研究的目的:
- 确定负责吸收PROTAC和其他大/极性分子的细胞点和机制.
- 制定提高PROTAC药物的输送和抗瘤功效的策略.
主要方法:
- 基于生物化化学探针的目标捕捞.
- 基因敲击和敲击方式.
- 使用前药物策略对PROTAC进行结构修改.
主要成果:
- 鉴定了分化集群36 (CD36) 作为一种关键蛋白质,可以结合并促进各种PROTAC和大/极小分子药物的吸收.
- 证明CD36通过早期内体抗原1 (EEA1) / Ras相关蛋白5A (Rab5) 内体途径进行吸收.
- 开发了一种新的化学内细胞药物化学策略,以增强PROTAC与CD36的结合.
- 通过提高透性和可溶性,显著提高了PROTACs的抗瘤功效.
结论:
- CD36是PROTAC和其他具有挑战性的药物分子的关键转运体.
- 针对CD36提供了一个有前途的策略来提高药物输送和治疗结果.
- 基于原药的修改可以有效地用于优化PROTACs的CD36介导输送和抗瘤活性.
更多相关视频
12:48Purification of the Membrane Compartment for Endoplasmic Reticulum-associated Degradation of Exogenous Antigens in Cross-presentation
Published on: August 21, 2017
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
相关概念视频
Receptor-mediated Endocytosis
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Export of Misfolded Proteins out of the ER
Intralumenal Vesicles and Multivesicular Bodies
Tail-anchoring of Proteins in the ER Membrane
Translocation of Proteins into the Mitochondria
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
